A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
